Physician profile
John B Cox
NPI 1477572063
$701.95
in general payments reported to CMS, 2019-2025
10 companies · $93.07 in 2025
The $93.07 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $56.79 · 2022: $226 · 2023: $166 · 2024: $161 · 2025: $93.07.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $420.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $419.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $443.72 | 2022-2024 | Target, Trevo, Surpass Evolve |
| Telix Pharmaceuticals | $93.07 | 2025 | Illuccix |
| Allergan, INC. | $56.79 | 2020 | |
| Abbott Laboratories | $34.20 | 2022 | |
| Tersera Therapeutics LLC | $20.19 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $19.82 | 2023 | Andexxa |
| Octapharma USA, INC. | $17.15 | 2022 | |
| Alcon Vision LLC | $17.01 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,351,444.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Cox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.